MAPS Israel

What MAPS Israel does

MAPS Israel is an Israeli non-profit organization (Israeli registration 516398716) headquartered in Hod Hasharon that develops and delivers psychedelic-assisted psychotherapy research and clinical education programs in Israel. Operating as a fiscally sponsored project of the US-based Multidisciplinary Association for Psychedelic Studies (MAPS, founded 1986, 501(c)(3) tax ID 59-2751953), it conducts multi-center clinical trials of MDMA-assisted and psilocybin-assisted psychotherapy for PTSD, treatment-resistant depression, eating disorders, and moral injury, in partnership with the Israeli Ministry of Health and six major hospital systems (Rambam, Sheba, Lev Hasharon, Be'er Yaakov, Haemek, Herzog). Its flagship HealingOct7 Project targets trauma in survivors of the October 7 Hamas attacks, including Nova music festival survivors and Gaza-border community residents, with planned MDMA-assisted group therapy multisite studies informed by the Lykos Phase 3 MAPP2 results (71.2% of patients no longer met PTSD criteria; 86.5% experienced symptom reduction).

The organization's product surface comprises two pillars: research programs (HealingOct7, MDMA-assisted group psychotherapy studies, psilocybin/MDMA-assisted psychotherapy across multiple indications) and educational programs (a one-year Psychedelic Psychotherapy Annual Program launched Autumn 2024 in collaboration with Reichman University and Hakomi Institute of Israel, and an MDMA-Assisted Therapy Education Program in collaboration with Lykos Therapeutics). MAPS Israel also publishes educational resources including a Hebrew translation of Stanislav Grof's 'The Way of the Psychonaut.'

The business model is entirely donation-funded; the organization does not charge for clinical services or therapy, and accepts contributions via Israeli bank transfer, PayPal, and US donations through Causematch under MAPS' fiscal sponsorship. It is staffed by approximately 7 team members led by Co-founder and CEO Keren Tzarfaty Ph.D., with named financial supporters including The DARE Foundation (Orli and Zack Rinat) and individual donors. The organization does not operate a traditional equity-based ownership structure and is governed by a board that includes Shiri Regev Messalem Ph.D. and Prof. Oded Maimon.

Name

MAPS Israel

Legal name

MAPS Israel

Website

https://maps-israel.org

Company type

Private

Operating status

Operating

Short description

MAPS Israel is an Israeli non-profit research and education organization that runs MDMA- and psilocybin-assisted psychotherapy clinical trials and therapist training programs, fiscally sponsored by US-based MAPS, serving PTSD and trauma survivors (including October 7 attack survivors), treatment-resistant depression and eating disorder patients, and mental health professionals across Israeli hospital and university partners.

Ownership category

akta.pro rank

Product category

Mental Health Research and Psychedelic-Assisted Psychotherapy

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Voluntary Health Organizations (813212)

SIC

Services-Social Services (8300), Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Mental Health & Crisis Support Services (BPAGACAD)

akta.pro secondary industry

Outpatient Rehabilitation & Physical/Occupational/Speech Therapy Centers (HLAFABAB)

Keywords

• Psychedelic-assisted psychotherapy
• MDMA-assisted therapy research
• Psilocybin clinical trials
• Mental health research
• Therapist training programs

Headquarters

HQ city

Hod Hasharon

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Donations and Charitable Contributions: The organization is entirely funded by donations. Accepts Israeli bank transfers, PayPal, and US donations through Causematch. Fiscal sponsorship by MAPS (501(c)(3) public charity).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

MAPS Israel is an Israeli non-profit (registration n.516398716) that develops and conducts clinical research on psychedelic-assisted psychotherapy—primarily MDMA-assisted and psilocybin-assisted treatments for PTSD, treatment-resistant depression, eating disorders, and moral injury—under Israeli Ministry of Health oversight and in collaboration with major Israeli hospitals. It also delivers professional training programs for mental health practitioners, including a one-year Psychedelic Psychotherapy Annual Program with Reichman University and the Hakomi Institute of Israel, and runs the HealingOct7 trauma response program for October 7th survivors.

Product overview

MAPS Israel operates as a non-profit organization focused on psychedelic research and education rather than a traditional technology product company. The organization offers two main program categories: (1) Educational programs including a Psychedelic Psychotherapy Annual Program (one-year training in collaboration with Reichman University and Hakomi Institute of Israel) and an MDMA-Assisted Therapy Education Program (in partnership with Lykos Therapeutics); and (2) Research programs including HealingOct7 (trauma therapy for October 7th survivors), MDMA-assisted group psychotherapy studies for PTSD across various populations (veterans, Nova survivors, border communities), and psilocybin/MDMA-assisted psychotherapy for treatment-resistant depression, eating disorders, and moral injury. Additionally, MAPS Israel publishes educational resources including Stanislav Grof's book 'The Way of the Psychonaut' in Hebrew.

Differentiator

Problem solved

Functional benefit

Products and services

• Psychedelic Psychotherapy Annual Program A one-year professional training program in psychedelic-assisted psychotherapy developed in collaboration with Reichman University, the Hakomi Institute of Israel, and MAPS Israel. The program covers theoretical and educational frameworks for therapeutic work with altered states of consciousness, rooted in depth psychology, integrative experiential psychotherapy, and insights from spiritual traditions. It is designed for mental health professionals seeking formal training in psychedelic therapy.
• MDMA-Assisted Therapy Education Program An educational program developed in collaboration with Lykos Therapeutics that trains attendees on the inner-directed therapeutic approach used in investigational midomafetamine (MDMA)-assisted therapy clinical trials. The program includes an online portion and an in-person educational week, providing theoretical frameworks suitable for therapeutic work with altered states of consciousness. Designed for mental health professionals and clinicians.
• HealingOct7 Project A charitable project providing trauma-based therapy programs and crisis response for October 7th survivors, including individual and group therapy for Nova Rave massacre survivors and kibbutzim/moshavim survivors. MAPS Israel is working to initiate a group MDMA therapy multisite study for these survivors, inspired by positive Lykos Phase 3 results.
• MDMA-Assisted Group Psychotherapy Studies Clinical research examining the potential of MDMA-assisted group psychotherapy for veterans with PTSD, Nova music festival survivors, and residents of villages, kibbutzim, and cities along Israel's southern border who experienced Hamas attacks. Studies are conducted at multiple Israeli medical centers and mental health institutions.
• The Way of the Psychonaut (Hebrew Edition) Hebrew translation of Stanislav Grof's book 'The Way of the Psychonaut' published by MAPS Israel in July 2024, available for purchase through the MAPS Israel website.

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• MAPS (Multidisciplinary Association for Psychedelic Studies)coreStrategic or Co-development Partner · 1 January 1986MAPS Israel collaborates with MAPS, an American non-profit organization founded in 1986. MAPS Israel operates under fiscal sponsorship of MAPS (501(c)(3) public charity, federal tax ID: 59-2751953). MAPS Israel uses licensed marks owned by MAPS with permission.
• Lykos TherapeuticscoreStrategic or Co-development PartnerCollaboration on MDMA-Assisted Therapy Education Program. Lykos Therapeutics (formerly MAPS Public Benefit Corporation) provides the investigational midomafetamine (MDMA) capsules for clinical trials and educational framework for the inner-directed therapeutic approach.
• Reichman UniversitycoreStrategic or Co-development PartnerCollaboration on Psychedelic Psychotherapy Annual Program - a one-year educational program for psychedelic therapy, launched Autumn 2024.
• Hakomi Institute of IsraelcoreStrategic or Co-development PartnerCollaboration on crisis response following October 7th attacks. Hakomi Institute of Israel and dozens of MAPS Israel-trained therapists organized therapeutic crisis response for survivors.
• Israeli Ministry of HealthcoreStrategic or Co-development PartnerStudies conducted with approval and cooperation of the Israeli Ministry of Health, ensuring regulatory oversight and compliance.
• Rambam Health Care CampusmajorStrategic or Co-development PartnerParticipating research center for MDMA-assisted psychotherapy multicenter study for early sexual abuse trauma.
• Sheba Medical CentermajorStrategic or Co-development PartnerParticipating center for MDMA-assisted and Psilocybin-assisted psychotherapy studies for eating disorders and PTSD with moral injury.
• Lev Hasharon Mental Health CentermajorStrategic or Co-development PartnerParticipating research center for MDMA-assisted psychotherapy multicenter studies.
• Be'er Yaakov Mental Health CentermajorStrategic or Co-development PartnerParticipating research center for MDMA-assisted psychotherapy studies for therapists and healthy volunteers.
• Haemek Medical CentermajorStrategic or Co-development PartnerParticipating center for MDMA-assisted individual and group psychotherapy for PTSD with Moral Injury.
• Herzog Medical CentermajorStrategic or Co-development PartnerParticipating center through Metiv Organization for MDMA-assisted psychotherapy for PTSD with moral injury.
• Nova Music Festival SurvivorscoreStrategic or Co-development PartnerTarget population for MDMA-assisted group psychotherapy research studies addressing unique psychological needs of October 7th attack survivors.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Field Trip Health: Operated psychedelic-assisted therapy clinics; provides ketamine-based psychotherapy with adjacent MDMA/psilocybin research pipeline — comparable psychedelic mental health treatment focus.
• MindMed: Clinical-stage psychedelic medicine company developing LSD and MDMA-based therapies for mental health; comparable product category (MDMA-assisted therapy) and target conditions.
• MAPS (Multidisciplinary Association for Psychedelic Studies): The US-based parent non-profit and global leader in psychedelic therapy research, founded in 1986. MAPS Israel is a fiscally sponsored project of MAPS, sharing mission, methodology, and brand lineage.
• Compass Pathways: Clinical-stage company developing psilocybin therapy for treatment-resistant depression; operates in the same psychedelic-assisted psychotherapy category and shares the TRD use case with MAPS Israel.
• Imperial College Centre for Psychedelic Research: Academic research center at Imperial College London conducting psilocybin and MDMA clinical trials; comparable research-only mission and clinical methodology.
• Usona Institute: Non-profit psychedelic research organization sponsoring psilocybin clinical trials for major depressive disorder; comparable mission, non-profit structure, and indication overlap with MAPS Israel's psilocybin TRD work.
• Beckley Foundation: Non-profit psychedelic research organization funding and coordinating clinical trials globally; comparable non-profit research mission and donor-funded model.
• Johns Hopkins Center for Psychedelic and Consciousness Research: Academic psychedelic research center running clinical trials on psilocybin for depression, PTSD, and addiction; comparable academic-clinical research model and indication overlap.

Broad incumbents

• Lykos Therapeutics: Formerly MAPS Public Benefit Corporation; develops midomafetamine (MDMA) for PTSD and provides the investigational drug and therapeutic framework underlying MAPS Israel's clinical trials.

Emerging players

• Hakomi Institute of Israel: Mindfulness-based somatic psychotherapy training organization; partnered with MAPS Israel on crisis response and educational programs, operating in the same experiential psychotherapy training niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MAPS Israel